Frédéric Barbut

Prof. Dr. Frédéric Barbut

National Reference Laboratory for Clostridium difficile, AP-HP Assistance Publique - Hopitaux de Paris, 75004 Paris, France
orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2007 in Clinical Microbiology and Infection
Verified
Journal Article
Open access
PDF file
FBFrédéric Barbut
Frédéric Barbut
PMP. Mastrantonio
P. Mastrantonio
MDM. Delmée
M. Delmée
JBJ. Brazier
J. Brazier
EKE. Kuijper
E. Kuijper
IPI. Poxton
I. Poxton
A 2-month prospective study of Clostridium difficile infections was conducted in 38 hospitals from 14 different European countries in order to obtain an overview of the phenotypic and genotypic features of clinical isolates of C. difficile during 2005. Of 411 isolates from diarrhoeagenic patients with suspected C. difficile-associated diarrhoea (CDAD), 354 were toxigenic, of which 86 (24.3%) were toxin-variant strains. Major toxinotypes included toxinotypes 0 (n = 268), V (n = 28), VIII (n = 22) and III (n = 25). MICs of metronidazole, vancomycin, erythromycin, clindamycin, moxifloxacin and tetracycline were determined using the Etest method. All the toxigenic strains were fully-susceptible to metronidazole and vancomycin. Resistance to erythromycin, clindamycin, tetracycline and moxifloxacin was found in 44.4%, 46.1%, 9.2% and 37.5% of the isolates, respectively. Sixty-six different PCR ribotypes were characterised, with the 027 epidemic strain accounting for 6.2% of isolates. This strain was positive for binary toxin genes, had an 18-bp deletion in the tcdC gene, and was resistant to both erythromycin and moxifloxacin. The mean incidence of CDAD was 2.45 cases/10 000 patient-days, but this figure varied widely among the participating hospitals. Patients infected with the 027 strain were more likely to have a severe disease (OR 3.29, 95% CI 1.19-9.16, p 0.008) and to have been specifically treated with metronidazole or vancomycin (OR 7.46, 95% CI 1.02-154, p 0.02). Ongoing epidemiological surveillance of cases of CDAD, with periodic characterisation of the strains involved, is required to detect clustering of cases in time and space and to monitor the emergence of specific highly virulent clones.

1 June 2009 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
FBFrédéric Barbut
Frédéric Barbut
DMD. Menuet
D. Menuet
MVM. Verachten
M. Verachten
EGE. Girou
E. Girou
Objective.: To compare a hydrogen peroxide dry-mist system and a 0.5% hypochlorite solution with respect to their ability to disinfectClostridiumdifficile-contaminated surfaces in vitro and in situ.Design.: Prospective, randomized, before-after trial.Setting.: Two French hospitals affected byC. difficile.Intervention.: In situ efficacy of disinfectants was assessed in rooms that had housed patients withC. difficileinfection. A prospective study was performed at 2 hospitals that involved randomization of disinfection processes. When a patient withC. difficileinfection was discharged, environmental contamination in the patient's room was evaluated before and after disinfection. Environmental surfaces were sampled forC. difficileby use of moistened swabs; swab samples were cultured on selective plates and in broth. Both disinfectants were tested in vitro with a spore-carrier test; in this test, 2 types of material, vinyl polychloride (representative of the room's floor) and laminate (representative of the room's furniture), were experimentally contaminated with spores from 3C. difficilestrains, including the epidemic clone ribotype 027-North American pulsed-field gel electrophoresis type 1.Results.: There were 748 surface samples collected (360 from rooms treated with hydrogen peroxide and 388 from rooms treated with hypochlorite). Before disinfection, 46 (24%) of 194 samples obtained in the rooms randomized to hypochlorite treatment and 34 (19%) of 180 samples obtained in the rooms randomized to hydrogen peroxide treatment showed environmental contamination. After disinfection, 23 (12%) of 194 samples from hypochlorite-treated rooms and 4 (2%) of 180 samples from hydrogen peroxide treated rooms showed environmental contamination, a decrease in contamination of 50% after hypochlorite decontamination and 91% after hydrogen peroxide decontamination (P< .005). The in vitro activity of 0.5% hypochlorite was time dependent. The mean (±SD) reduction in initial log10 bacterial count was 4.32 ± 0.35 log10 colony-forming units after 10 minutes of exposure to hypochlorite and 4.18 ± 0.8 logl0 colony-forming units after 1 cycle of hydrogen peroxide decontamination.Conclusion.: In situ experiments indicate that the hydrogen peroxide dry-mist disinfection system is significantly more effective than 0.5% sodium hypochlorite solution at eradicating Сdifficilespores and might represent a new alternative for disinfecting the rooms of patients withC. difficileinfection.

1 May 2018 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
CGC. Gateau
C. Gateau
JCJ. Couturier
J. Couturier
JCJ. Coia
J. Coia
FBFrédéric Barbut
Frédéric Barbut

1 August 2011 in Current Opinion in Infectious Diseases
Verified
Journal Article
Closed access
FBFrédéric Barbut
Frédéric Barbut
GJGabrielle Jones
Gabrielle Jones
CECatherine Eckert
Catherine Eckert
The epidemiology of Clostridium difficile infections (CDIs) has dramatically changed over the last decade in both North America and Europe. The objectives of this review are to highlight the recent epidemiological data and to provide an overview of the current knowledge of infection control measures. Since 2003, many countries have reported increased incidence of CDI and outbreaks of severe cases of CDI. This trend is assumed to be due, in part, to the emergence and rapid spread of a 'hypervirulent' strain, known as 027/BI/NAP1. This strain has become endemic in many hospitals in North America and Europe. CDI rates have also increased in the community and new genotypes (e.g. PCR ribotype 078) are emerging in both humans and animals. To prevent cross-contamination and to reduce the incidence of CDI, infection control guidelines, based primarily on experience of hospitals during outbreaks, have been recently updated in Europe and the United States. CDI prevention relies on a bundle of measures including antimicrobial stewardship, prompt diagnosis, and the implementation of contact precautions. Currently, most of these measures have appeared effective in controlling outbreaks, but the best methods to reduce CDI incidence in settings of endemicity are still unknown. The recent changes in CDI epidemiology have pushed infection control healthcare workers and scientific societies to revisit and update their guidelines for infection control.

1 April 2015 in Journal of Hospital Infection
Verified
Journal Article
Closed access
FBFrédéric Barbut
Frédéric Barbut

1 February 2014 in Clinical Microbiology and Infection
Verified
Journal Article
Open access
PDF file
FBFrédéric Barbut
Frédéric Barbut
LSL. Surgers
L. Surgers
CEC. Eckert
C. Eckert
BVB. Visseaux
B. Visseaux
MCM. Cuingnet
M. Cuingnet
VLV. Lalande
V. Lalande
A rapid and accurate diagnosis of Clostridium difficile infection (CDI) is essential for patient management and implementation of infection control measures. During a prospective time-series study, we compared the impact of three different diagnostic strategies on patient care. Each strategy was tested during a 3-month period: P1 (diagnosis based on the stool cytotoxicity assay and the toxigenic culture), P2 (diagnosis based on PCR) and P3 (two-step algorithm based on glutamate dehydrogenase detection followed by nucleic acid amplification test). The following criteria were used to assess the quality of patient management: (i) time for result reporting, (ii) frequency of repeat testing within 7 days, (iii) time elapsed between stool collection and beginning of treatment for patients with CDI, and (iv) frequency of empirical treatment for patients without CDI. Of 1122 stool samples (P1 n = 359, P2 n = 374, P3 n = 389), 36 (10.0%), 47 (12.3%) and 48 (12.3%) were positive for C. difficile during P1, P2 and P3, respectively. The time for reporting of a positive or a negative result was significantly shorter and the frequency of redundant stool samples within 7 days was lower during P2 and P3 than during P1. Patients with CDI were specifically treated with vancomycin or metronidazole earlier during P2 and P3 than patients from P1 (0.5 ± 0.5 days and 1.0 ± 1.8 days vs. 2.0 ± 1.7 days). The empirical therapy among patients without CDI decreased from 13.6% during P1 to 6.4% during P2 and 5.6% during P3. A rapid CDI diagnosis impacts positively on patient care.